Modulation of insulin action

Diabetologia

Volumn 47, Issue 2, 2004, Pages 170-184

  Pirola, L ^a   Johnston, A M ^a   Van Obberghen, E ^a  

^a INSERM   (France)

Author keywords

Hyperglycaemia; Hyperinsulinaemia; Insulin resistance; Insulin signalling; IRS proteins; Serine threonine phosphorylation; SOCS proteins

Indexed keywords

CYTOKINE; FATTY ACID; GLUCOSAMINE; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; TUMOR NECROSIS FACTOR ALPHA;

AUTOPHOSPHORYLATION; CHO CELL; ENZYME ACTIVITY; FATTY ACID OXIDATION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HORMONAL REGULATION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN SYNTHESIS; LIPID METABOLISM; PANCREAS ISLET BETA CELL; PHOSPHOLIPID SYNTHESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PHOSPHORYLATION; RADIOIMMUNOASSAY; RECEPTOR DOWN REGULATION; REVIEW;

ANIMALS; CYTOKINES; FATTY ACIDS; GENE EXPRESSION REGULATION; GLUCOSAMINE; GLYCOSYLATION; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; INSULIN; INSULIN RESISTANCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, BIOLOGICAL; MULTIENZYME COMPLEXES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, INSULIN; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANSCRIPTION FACTORS;

EID: 1542285112     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-003-1313-3     Document Type: Review

References (149)

1. Lizcano JM, Alessi DR (2002) The insulin signalling pathway. Curr Biol 12:R236-R238
2. Kido Y, Nakae J, Accili D (2001) Clinical review 125: the insulin receptor and its cellular targets. J Clin Endocrinol Metab 86:972-979
3. Cai D, Dhe-Paganon S, Melendez PA, Lee J, Shoelson SE (2003) Two new substrates in insulin signaling, IRS5/ DOK4 and IRS6/DOK5. J Biol Chem 278:25323-25330
4. White MF (1997) The insulin signalling system and the IRS proteins. Diabetologia 40:S2-S17
5. Saltiel AR, Kahn CR (2001) Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414:799-806
6. Bertrand F, Atfi A, Cadoret A et al. (1998) A role for nuclear factor kappaB in the antiapoptotic function of insulin. J Biol Chem 273:2931-2938
7. Pandey SK, He HJ, Chesley A, Juhaszova M, Crow MT, Bernier M (2002) Wortmannin-sensitive pathway is required for insulin-stimulated phosphorylation of inhibitor kappaBalpha. Endocrinology 143:375-385
8. Vanhaesebroeck B, Alessi DR (2000) The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 346:561-576
9. Brazil DP, Hemmings BA (2001) Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 26:657-664
10. Khan AH, Pessin JE (2002) Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways. Diabetologia 45:1475-1483
11. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785-789
12. Girard J, Perdereau D, Foufelle F, Prip-Buus C, Ferre P (1994) Regulation of lipogenic enzyme gene expression by nutrients and hormones. FASEB J 8:36-42
13. O'Brien RM, Streeper RS, Ayala JE, Stadelmaier BT, Hornbuckle LA (2001) Insulin-regulated gene expression. Biochem Soc Trans 29:552-558
14. Baumann CA, Ribon V, Kanzaki M et al. (2000) CAP defines a second signalling pathway required for insulin-stimulated glucose transport. Nature 407:202-207
15. Chiang SH, Baumann CA, Kanzaki M et al. (2001) Insulin-stimulated GLUT4 translocation requires the CAP-dependent activation of TC10. Nature 410:944-948
16. Chiang SH, Hwang J, Legendre M, Zhang M, Kimura A, Saltiel AR (2003) TCGAP, a multidomain Rho GTPase-activating protein involved in insulin-stimulated glucose transport. EMBO J 22:2679-2691
17. Somwar R, Koterski S, Sweeney G et al. (2002) A dominant-negative p38 MAPK mutant and novel selective inhibitors of p38 MAPK reduce insulin-stimulated glucose uptake in 3T3-L1 adipocytes without affecting GLUT4 translocation. J Biol Chem 277:50386-50395
18. Kahn SE (2003) The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46:3-19
19. Kahn CR, Bruning JC, Michael MD, Kulkarni RN (2000) Knockout mice challenge our concepts of glucose homeostasis and the pathogenesis of diabetes mellitus. J Pediatr Endocrinol Metab 13:1377-1384
20. Hribal ML, Perego L, Lovari S et al. (2003) Chronic hyperglycemia impairs insulin secretion by affecting insulin receptor expression, splicing, and signaling in RIN beta cell line and human islets of Langerhans. FASEB J 17:1340-1342
21. Sesti G (2002) Apoptosis in the beta cells: cause or consequence of insulin secretion defect in diabetes? Ann Med 34:444-450
22. LeRoith D (2002) Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am J Med 113:3S-11S
23. Accili D, Cama A, Barbetti F, Kadowaki H, Kadowaki T, Taylor SI (1992) Insulin resistance due to mutations of the insulin receptor gene: an overview. J Endocrinol Invest 15:857-864
24. Le Marchand-Brustel Y, Gremeaux T, Ballotti R, Van Obberghen E (1985) Insulin receptor tyrosine kinase is defective in skeletal muscle of insulin-resistant obese mice. Nature 315:676-679
25. Arner P, Pollare T, Lithell H, Livingston JN (1987) Defective insulin receptor tyrosine kinase in human skeletal muscle in obesity and type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30:437-440
26. Harrison LC, Itin A, Kasuga M, Van Obberghen E (1982) The insulin receptor on the human lymphocyte: insulin-induced down-regulation of 126,000 and 90,000 glycosylated subunits. Diabetologia 22:233-238
27. Taylor SI, Samuels B, Roth J et al. (1982) Decreased insulin binding in cultured lymphocytes from two patients with extreme insulin resistance. J Clin Endocrinol Metab 54:919-930
28. Bossenmaier B, Strack V, Stoyanov B et al. (2000) Serine residues 1177/78/82 of the insulin receptor are required for substrate phosphorylation but not autophosphorylation. Diabetes 49:889-895
29. Federici M, Lauro D, D'Adamo M et al. (1998) Expression of insulin/IGF-I hybrid receptors is increased in skeletal muscle of patients with chronic primary hyperinsulinemia. Diabetes 47:87-92
30. Federici M, Porzio O, Lauro D et al. (1998) Increased abundance of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of obese subjects is correlated with in vivo insulin sensitivity. J Clin Endocrinol Metab 83:2911-2915
31. Zhang B, Salituro G, Szalkowski D et al. (1999) Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science 284:974-977
32. Saad MJ, Araki E, Miralpeix M, Rothenberg PL, White MF, Kahn CR (1992) Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistance. J Clin Invest 90:1839-1849
33. Jullien D, Tanti JF, Heydrick SJ et al. (1993) Differential effects of okadaic acid on insulin-stimulated glucose and amino acid uptake and phosphatidylinositol 3-kinase activity. J Biol Chem 268:15246-15251
34. Roth RA, Liu F, Chin JE (1994) Biochemical mechanisms of insulin resistance. Horm Res 41:51-55
35. Qiao LY, Goldberg JL, Russell JC, Sun XJ (1999) Identification of enhanced serine kinase activity in insulin resistance. J Biol Chem 274:10625-10632
36. Sun XJ, Goldberg JL, Qiao LY, Mitchell JJ (1999) Insulin-induced insulin receptor substrate-1 degradation is mediated by the proteasome degradation pathway. Diabetes 48:1359-1364
37. Haruta T, Uno T, Kawahara J et al. (2000) A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol 14:783-794
38. Tzivion G, Avruch J (2002) 14-3-3 proteins: active cofactors in cellular regulation by serine/threonine phosphorylation. J Biol Chem 277:3061-3064
39. Craparo A, Freund R, Gustafson TA (1997) 14-3-3 (epsilon) interacts with the insulin-like growth factor I receptor and insulin receptor substrate I in a phosphoserine-dependent manner. J Biol Chem 272:11663-11669
40. Ogihara T, Isobe T, Ichimura T et al. (1997) 14-3-3 protein binds to insulin receptor substrate-1, one of the binding sites of which is in the phosphotyrosine binding domain. J Biol Chem 272:25267-25274
41. Kosaki A, Yamada K, Suga J, Otaka A, Kuzuya H (1998) 14-3-3beta protein associates with insulin receptor substrate 1 and decreases insulin-stimulated phosphatidylinositol 3′-kinase activity in 3T3L1 adipocytes. J Biol Chem 273:940-944
42. Xiang X, Yuan M, Song Y, Ruderman N, Wen R, Luo Z (2002) 14-3-3 facilitates insulin-stimulated intracellular trafficking of insulin receptor substrate 1. Mol Endocrinol 16:552-562
43. Dhand R, Hiles I, Panayotou G et al. (1994) PI 3-kinase is a dual specificity enzyme: autoregulation by an intrinsic protein-serine kinase activity. EMBO J 13:522-533
44. Lam K, Carpenter CL, Ruderman NB, Friel JC, Kelly KL (1994) The phosphatidylinositol 3-kinase serine kinase phosphorylates IRS-1. Stimulation by insulin and inhibition by Wortmannin. J Biol Chem 269:20648-20652
45. Egawa K, Sharma PM, Nakashima N et al. (1999) Membrane-targeted phosphatidylinositol 3-kinase mimics insulin actions and induces a state of cellular insulin resistance. J Biol Chem 274:14306-14314
46. Eldar-Finkelman H, Krebs EG (1997) Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proc Natl Acad Sci USA 94:9660-9664
47. Ozes ON, Akca H, Mayo LD et al. (2001) A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc Natl Acad Sci USA 98:4640-4645
48. Liu YF, Paz K, Herschkovitz A et al. (2001) Insulin stimulates PKCzeta -mediated phosphorylation of insulin receptor substrate-1 (IRS-1). A self-attenuated mechanism to negatively regulate the function of IRS proteins. J Biol Chem 276:14459-14465
49. Ravichandran LV, Esposito DL, Chen J, Quon MJ (2001) Protein kinase C-zeta phosphorylates insulin receptor substrate-1 and impairs its ability to activate phosphatidylinositol 3-kinase in response to insulin. J Biol Chem 276:3543-3549
50. Sykiotis GP, Papavassiliou AG (2001) Serine phosphorylation of insulin receptor substrate-1: a novel target for the reversal of insulin resistance. Mol Endocrinol 15:1864-1869
51. Aguirre V, Uchida T, Yenush L, Davis R, White MF (2000) The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 275:9047-9054
52. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF (2002) Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 277:1531-1537
53. Hirosumi J, Tuncman G, Chang L et al. (2002) A central role for JNK in obesity and insulin resistance. Nature 420:333-336
54. Rui L, Aguirre V, Kim JK et al. (2001) Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest 107:181-189
55. Lee YH, Giraud J, Davis RJ, White MF (2003) c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J Biol Chem 278:2896-2902
56. Greene MW, Sakaue H, Wang L, Alessi DR, Roth RA (2003) Modulation of insulin-stimulated degradation of human insulin receptor substrate-1 by serine 312 phosphorylation. J Biol Chem 278:8199-8211
57. Bouzakri K, Roques M, Gual P et al. (2003) Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes. Diabetes 52:1319-1325
58. De Fea K, Roth RA (1997) Modulation of insulin receptor substrate-1 tyrosine phosphorylation and function by mitogen-activated protein kinase. J Biol Chem 272:31400-31406
59. Engelman JA, Berg AH, Lewis RY, Lisanti MP, Scherer PE (2000) Tumor necrosis factor alpha-mediated insulin resistance, but not dedifferentiation, is abrogated by MEK1/2 inhibitors in 3T3-L1 adipocytes. Mol Endocrinol 14:1557-1569
60. Cusi K, Maezono K, Osman A et al. (2000) Insulin resistance differentially affects the PI 3-kinase-and MAP kinase-mediated signaling in human muscle. J Clin Invest 105:311-320
61. Fujishiro M, Gotoh Y, Katagiri H et al. (2003) Three mitogen-activated protein kinases inhibit insulin signaling by different mechanisms in 3T3-L1 adipocytes. Mol Endocrinol 17:487-497
62. Carlson CJ, Koterski S, Sciotti RJ, Poccard GB, Rondinone CM (2003) Enhanced basal activation of mitogen-activated protein kinases in adipocytes from type 2 diabetes: potential role of p38 in the downregulation of GLUT4 expression. Diabetes 52:634-641
63. Huang C, Somwar R, Patel N, Niu W, Torok D, Klip A (2002) Sustained exposure of L6 myotubes to high glucose and insulin decreases insulin-stimulated GLUT4 translocation but upregulates GLUT4 activity. Diabetes 51:2090-2098
64. Winder WW, Hardie DG (1999) AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 277:E1-E10
65. Jakobsen SN, Hardie DG, Morrice N, Tornqvist HE (2001) 5′-AMP-activated protein kinase phosphorylates IRS-1 on Ser-789 in mouse C2C12 myotubes in response to 5-aminoimidazole-4-carboxamide riboside. J Biol Chem 276:46912-46916
66. Horike N, Takemori H, Katoh Y et al. (2003) Adipose-specific expression, phosphorylation of Ser794 in insulin receptor substrate-1, and activation in diabetic animals of salt-inducible kinase-2. J Biol Chem 278:18440-18447
67. Yuan M, Konstantopoulos N, Lee J et al. (2001) Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293:1673-1677
68. Kim JK, Kim YJ, Fillmore JJ et al. (2001) Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 108:437-446
69. Gao Z, Hwang D, Bataille F et al. (2002) Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. J Biol Chem 277:48115-48121
70. Gao Z, Zuberi A, Quon MJ, Dong Z, Ye J (2003) Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases. J Biol Chem 278:24944-24950
71. Burke JR (2003) Targeting I kappa B kinase for the treatment of inflammatory and other disorders. Curr Opin Drug Discov Devel 6:720-728
72. Farah S, Agazie Y, Ohan N, Ngsee JK, Liu XJ (1998) A rho-associated protein kinase, ROKalpha, binds insulin receptor substrate-1 and modulates insulin signaling. J Biol Chem 273:4740-4746
73. Begum N, Sandu OA, Ito M, Lohmann SM, Smolenski A (2002) Active Rho kinase (ROK-alpha) associates with insulin receptor substrate-1 and inhibits insulin signaling in vascular smooth muscle cells. J Biol Chem 277:6214-6222
74. Alexander WS (2002) Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2:410-416
75. Yoshimura A, Ohkubo T, Kiguchi T et al. (1995) A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. Embo J 14:2816-28126
76. Starr R, Willson TA, Viney EM et al. (1997) A family of cytokine-inducible inhibitors of signalling. Nature 387:917-921
77. Kile BT, Schulman BA, Alexander WS, Nicola NA, Martin HM, Hilton DJ (2002) The SOCS box: a tale of destruction and degradation. Trends Biochem Sci 27:235-241
78. Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E (2000) SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 275:15985-15991
79. Emanuelli B, Peraldi P, Filloux C et al. (2001) SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 276:47944-47949
80. Sadowski CL, Choi TS, Le M, Wheeler TT, Wang LH, Sadowski HB (2001) Insulin Induction of SOCS-2 and SOCS-3 mRNA expression in C2C12 Skeletal Muscle Cells Is Mediated by Stat5*. J Biol Chem 276:20703-20710
81. Dey BR, Furlanetto RW, Nissley P (2000) Suppressor of cytokine signaling (SOCS)-3 protein interacts with the insulin-like growth factor-I receptor. Biochem Biophys Res Commun 278:38-43
82. Dey BR, Spence SL, Nissley P, Furlanetto RW (1998) Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor. J Biol Chem 273:24095-24101
83. Kaburagi Y, Momomura K, Yamamoto-Honda R et al. (1993) Site-directed mutagenesis of the juxtamembrane domain of the human insulin receptor. J Biol Chem 268:16610-16622
84. Mooney RA, Senn J, Cameron S et al. (2001) Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem 276:25889-25893
85. Kawazoe Y, Naka T, Fujimoto M et al. (2001) Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylation. J Exp Med 193:263-269
86. Rui L, Yuan M, Frantz D, Shoelson S, White MF (2002) SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 277:42394-42398
87. Krebs DL, Uren RT, Metcalf D et al. (2002) SOCS-6 binds to insulin receptor substrate 4, and mice lacking the SOCS-6 gene exhibit mild growth retardation. Mol Cell Biol 22:4567-4578
88. Krebs DL, Hilton DJ (2003) A new role for SOCS in insulin action. Suppressor of cytokine signaling. Sci STKE 2003(169):PE6
89. Andreelli F, Laville M, Ducluzeau PH et al. (1999) Defective regulation of phosphatidylinositol-3-kinase gene expression in skeletal muscle and adipose tissue of non-insulin-dependent diabetes mellitus patients. Diabetologia 42:358-364
90. Tremblay F, Lavigne C, Jacques H, Marette A (2001) Defective insulin-induced GLUT4 translocation in skeletal muscle of high fat-fed rats is associated with alterations in both Akt/protein kinase B and atypical protein kinase C (zeta/lambda) activities. Diabetes 50:1901-1910
91. Mauvais-Jarvis F, Ueki K, Fruman DA et al. (2002) Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J Clin Invest 109:141-149
92. Terauchi Y, Tsuji Y, Satoh S et al. (1999) Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat Genet 21:230-235
93. Carvalho E, Jansson PA, Nagaev I, Wenthzel AM, Smith U (2001) Insulin resistance with low cellular IRS-1 expression is also associated with low GLUT4 expression and impaired insulin-stimulated glucose transport. FASEB J 15:1101-1103
94. Miele C, Formisano P, Condorelli G et al. (1997) Abnormal glucose transport and GLUT1 cell-surface content in fibroblasts and skeletal muscle from NIDDM and obese subjects. Diabetologia 40:421-429
95. Zhande R, Mitchell JJ, Wu J, Sun XJ (2002) Molecular mechanism of insulin-induced degradation of insulin receptor substrate 1. Mol Cell Biol 22:1016-1026
96. Rui L, Fisher TL, Thomas J, White MF (2001) Regulation of insulin/insulin-like growth factor-1 signaling by proteasome-mediated degradation of insulin receptor substrate-2. J Biol Chem 276:40362-40367
97. Buren J, Liu HX, Lauritz J, Eriksson JW (2003) High glucose and insulin in combination cause insulin receptor substrate-1 and -2 depletion and protein kinase B desensitisation in primary cultured rat adipocytes: possible implications for insulin resistance in type 2 diabetes. Eur J Endocrinol 148:157-167
98. Pirola L, Bonnafous S, Johnston AM, Chaussade C, Portis F, Van Obberghen E (2003) Phosphoinositide 3-kinase-mediated reduction of insulin receptor substrate-1/2 protein expression via different mechanisms contributes to the insulin-induced desensitization of its signaling pathways in L6 muscle cells. J Biol Chem 278:15641-15651
99. Paz K, Liu YF, Shorer H et al. (1999) Phosphorylation of insulin receptor substrate-1 (IRS-1) by protein kinase B positively regulates IRS-1 function. J Biol Chem 274:28816-28822
100. Esposito DL, Li Y, Vanni C et al. (2003) A novel T608R missense mutation in insulin receptor substrate-1 identified in a subject with type 2 diabetes impairs metabolic insulin signaling. J Clin Endocrinol Metab 88:1468-1475
101. Withers DJ, Gutierrez JS, Towery H et al. (1998) Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391:900-904
102. Nolan JJ, Freidenberg G, Henry R, Reichart D, Olefsky JM (1994) Role of human skeletal muscle insulin receptor kinase in the in vivo insulin resistance of noninsulin-dependent diabetes mellitus and obesity. J Clin Endocrinol Metab 78:471-477
103. Maegawa H, Shigeta Y, Egawa K, Kobayashi M (1991) Impaired autophosphorylation of insulin receptors from abdominal skeletal muscles in nonobese subjects with NIDDM. Diabetes 40:815-819
104. Krook A, Bjornholm M, Galuska D et al. (2000) Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. Diabetes 49:284-292
105. Caro JF, Sinha MK, Raju SM et al. (1987) Insulin receptor kinase in human skeletal muscle from obese subjects with and without noninsulin dependent diabetes. J Clin Invest 79:1330-1337
106. Klein HH, Vestergaard H, Kotzke G, Pedersen O (1995) Elevation of serum insulin concentration during euglycemic hyperinsulinemic clamp studies leads to similar activation of insulin receptor kinase in skeletal muscle of subjects with and without NIDDM. Diabetes 44:1310-1317
107. Rice KM, Turnbow MA, Garner CW (1993) Insulin stimulates the degradation of IRS-1 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 190:961-967
108. Carvalho E, Jansson PA, Axelsen M et al. (1999) Low cellular IRS 1 gene and protein expression predict insulin resistance and NIDDM. FASEB J 13:2173-2178
109. Rondinone CM, Wang LM, Lonnroth P, Wesslau C, Pierce JH, Smith U (1997) Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 94:4171-4175
110. Shao J, Yamashita H, Qiao L, Friedman JE (2000) Decreased Akt kinase activity and insulin resistance in C57BL/KsJ-Leprdb/db mice. J Endocrinol 167:107-115
111. Nawano M, Ueta K, Oku A et al. (1999) Hyperglycemia impairs the insulin signaling step between PI 3-kinase and Akt/PKB activations in ZDF rat liver. Biochem Biophys Res Commun 266:252-256
112. Oku A, Nawano M, Ueta K et al. (2001) Inhibitory effect of hyperglycemia on insulin-induced Akt/protein kinase B activation in skeletal muscle. Am J Physiol Endocrinol Metab 280:E816-E824
113. Yu C, Chen Y, Cline GW et al. (2002) Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 277:50230-50236
114. Kim YB, Shulman GI, Kahn BB (2002) Fatty acid infusion selectively impairs insulin action on Akt1 and protein kinase C lambda/zeta but not on glycogen synthase kinase-3. J Biol Chem 277:32915-32922
115. Dresner A, Laurent D, Marcucci M et al. (1999) Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 103:253-259
116. Schlaepfer IR, Pulawa LK, Ferreira LD, James DE, Capell WH, Eckel RH (2003) Increased expression of the SNARE accessory protein Munc18c in lipid-mediated insulin resistance. J Lipid Res 44:1174-1181
117. Wrede CE, Dickson LM, Lingohr MK, Briaud I, Rhodes CJ (2003) Fatty acid and phorbol ester-mediated interference of mitogenic signaling via novel protein kinase C isoforms in pancreatic beta-cells (INS-1). J Mol Endocrinol 30:271-286
118. Sacks FM (2002) Dietary fat, the Mediterranean diet, and health: reports from scientific exchanges, 1998 and 2000. Introduction. Am J Med 113:1S-4S.
119. Taouis M, Dagou C, Ster C, Durand G, Pinault M, Delarue J (2002) N-3 polyunsaturated fatty acids prevent the defect of insulin receptor signaling in muscle. Am J Physiol Endocrinol Metab 282:E664-E671
120. Grimble RF (2002) Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care 5:551-559
121. Spranger J, Kroke A, Mohlig M et al. (2003) Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52:812-817
122. Hotamisligil GS, Spiegelman BM (1994) Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 43:1271-1278
123. Hemi R, Paz K, Wertheim N, Karasik A, Zick Y, Kanety H (2002) Transactivation of ErbB2 and ErbB3 by tumor necrosis factor-alpha and anisomycin leads to impaired insulin signaling through serine/threonine phosphorylation of IRS proteins. J Biol Chem 277:8961-8969
124. Senn JJ, Klover PJ, Nowak IA, Mooney RA (2002) Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391-3399
125. Senn JJ, Klover PJ, Nowak IA et al. (2003) Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278:13740-13746
126. Shanmugam N, Reddy MA, Guha M, Natarajan R (2003) High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 52:1256-1264
127. Exel E van, Gussekloo J, Craen AJ de et al. (2002) Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes 51:1088-1092
128. Singh R, Barden A, Mori T, Beilin L (2001) Advanced glycation end-products: a review. Diabetologia 44:129-146
129. Abdel-Wahab YH, O'Harte FP, Ratcliff H, McClenaghan NH, Barnett CR, Flatt PR (1996) Glycation of insulin in the islets of Langerhans of normal and diabetic animals. Diabetes 45:1489-1496
130. Lindsay JR, McKillop AM, Mooney MH, O'Harte FP, Bell PM, Flatt PR (2003) Demonstration of increased concentrations of circulating glycated insulin in human Type 2 diabetes using a novel and specific radioimmunoassay. Diabetologia 46:475-478
131. Ruggiero-Lopez D, Rellier N, Lecomte M, Lagarde M, Wiernsperger N (1997) Growth modulation of retinal microvascular cells by early and advanced glycation products. Diabetes Res Clin Pract 34:135-142
132. Inagaki Y, Yamagishi S, Okamoto T, Takeuchi M, Amano S (2003) Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia 46:284-287
133. Treins C, Giorgetti-Peraldi S, Murdaca J, Van Obberghen E (2001) Regulation of vascular endothelial growth factor expression by advanced glycation end products. J Biol Chem 276:43836-43841
134. Makita Z, Yanagisawa K, Kuwajima S et al. (1995) Advanced glycation endproducts and diabetic nephropathy. J Diabetes Complications 9:265-268
135. Miele C, Riboulet A, Maitan MA et al. (2003) Human glycated albumin affects glucose metabolism in L6 skeletal muscle cells by impairing insulin-induced insulin receptor substrate (IRS) signaling through a protein kinase C{alpha}-mediated mechanism. J Biol Chem 278:47376-47387
136. Rossetti L (2000) Perspective: hexosamines and nutrient sensing. Endocrinology 141:1922-1925
137. Marshall S, Bacote V, Traxinger RR (1991) Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem 266:4706-4712
138. Ciaraldi TP, Carter L, Nikoulina S, Mudaliar S, McClain DA, Henry RR (1999) Glucosamine regulation of glucose metabolism in cultured human skeletal muscle cells: divergent effects on glucose transport/phosphorylation and glycogen synthase in non-diabetic and type 2 diabetic subjects. Endocrinology 140:3971-3980
139. Chen H, Ing BL, Robinson KA, Feagin AC, Buse MG, Quon MJ (1997) Effects of overexpression of glutamine:fructose-6-phosphate amidotransferase (GFAT) and glucosamine treatment on translocation of GLUT4 in rat adipose cells. Mol Cell Endocrinol 135:67-77
140. Vosseller K, Wells L, Lane MD, Hart GW (2002) Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 99:5313-5318
141. Chen G, Liu P, Thurmond DC, Elmendorf JS (2003) Glucosamine-induced insulin resistance is coupled to O-linked glycosylation of Munc18c. FEBS Lett 534:54-60
142. Parker GJ, Lund KC, Taylor RP, McClain DA (2003) Insulin resistance of glycogen synthase mediated by o-linked N-acetylglucosamine. J Biol Chem 278:10022-10027
143. Veerababu G, Tang J, Hoffman RT et al. (2000) Overexpression of glutamine:fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance. Diabetes 49:2070-2078
144. Cooksey RC, Hebert LF Jr, Zhu JH, Wofford P, Garvey WT, McClain DA (1999) Mechanism of hexosamine-induced insulin resistance in transgenic mice overexpressing glutamine:fructose-6-phosphate amidotransferase: decreased glucose transporter GLUT4 translocation and reversal by treatment with thiazolidinedione. Endocrinology 140:1151-1157
145. Pouwels MJ, Jacobs JR, Span PN, Lutterman JA, Smits P, Tack CJ (2001) Short-term glucosamine infusion does not affect insulin sensitivity in humans. J Clin Endocrinol Metab 86:2099-2103
146. Monauni T, Zenti MG, Cretti A et al. (2000) Effects of glucosamine infusion on insulin secretion and insulin action in humans. Diabetes 49:926-935
147. Kaneto H, Xu G, Song KH et al. (2001) Activation of the hexosamine pathway leads to deterioration of pancreatic beta-cell function through the induction of oxidative stress. J Biol Chem 276:31099-31104
148. Ramachandran C, Kennedy BP (2003) Protein tyrosine phosphatase 1B: a novel target for type 2 diabetes and obesity. Curr Top Med Chem 3:749-757
149. Asante-Appiah E, Kennedy BP (2003) Protein tyrosine phosphatases: the quest for negative regulators of insulin action. Am J Physiol Endocrinol Metab 284:E663-E670